Related Experiment Video
Updated: Apr 1, 2026

Generation of High Quality Chromatin Immunoprecipitation DNA Template for High-throughput Sequencing ChIP-seq
Published on: April 19, 2013
Genes associated with diabetes: potential for novel therapeutic targets?
Kazuo Hara1, Takashi Kadowaki2, Masato Odawara1
1a Division of Diabetes, Endocrinology and Metabolism , Tokyo Medical University , 6-7-1Nishi-shinjuku, Shinjuku-ku , Tokyo 160-0023 , Japan.
Introduction:
Type 2 diabetes (T2D) is a complex disease caused by an interaction between multiple genetic and environmental factors. T2D-associated loci identified by genome-wide association studies (GWAS) harbor the genes targeted by many clinically available drugs, supporting the idea that GWAS have the potential to discover novel genes for drug development.
Areas Covered:
This paper outlines, among the genes at those T2D-associated loci, the functional analysis of FTO, TCF7L2, SLC30A8, and MTNR1B, illustrating caveats we should be cautious about. This paper also reviews the current status of the compounds targeting the T2D-associated genes GCK, GKRP, ADIPOQ, and ADRA2A in clinical and preclinical phases.
Expert Opinion:
Functional analysis of those loci has fallen too far behind identification of T2D-associated loci. It is mandatory to define the true causal gene at the T2D-associated loci by using a variety of experimental techniques. The biggest challenge lies in the limited access to human tissues relevant to the pathogenesis of T2D. The ultimate goal of human genetic study is enabling personalized medicine based on the genetic information of individuals. More research will be needed to achieve this goal.
More Related Videos
Related Concept Videos
Pathophysiology of Diabetes
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Pharmacogenomics: Identification of New Drug Targets
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Diabetes Mellitus: Type 2 and Gestational
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Insulin: The Receptor and Signaling Pathways

